Now showing items 1-20 of 457

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03-25)
      BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11-09)
      BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ...
    • 3D modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. 

      Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; Gulati, A; Daley, F; Vyse, S; Huang, P; Lord, CJ; Farnie, G; Brennan, K; Natrajan, R (2016-08-11)
      The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations, ...
    • Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease 

      Simigdala, N; Pancholi, S; Ribas, R; Folkerd, E; Liccardi, G; Nikitorowicz-Buniak, J; Johnston, SR; Dowsett, M; Martin, L
    • Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. 

      Simigdala, N; Pancholi, S; Ribas, R; Folkerd, E; Liccardi, G; Nikitorowicz-Buniak, J; Johnston, SR; Dowsett, M; Martin, L-A (2018-08)
      BACKGROUND: Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80-90% of metastatic ...
    • Accountability in the NHS: the impact on cancer care. 

      Macklin-Doherty, A (2018)
      Accountability of service delivery is becoming increasingly complex and never has this been more apparent than in the field of Oncology. Cancer care has an unrivalled level of complexity not only in the heterogeneity of ...
    • Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast. 

      Naidoo, K; Beardsley, B; Carder, PJ; Deb, R; Fish, D; Girling, A; Hales, S; Howe, M; Wastall, LM; Lane, S; Lee, AHS; Philippidou, M; Quinn, C; Stephenson, T; Pinder, SE (2016-12)
      Although the UK National Institute for Health and Care Excellence guidelines recommend that in patients with biopsy-proven invasive lobular carcinoma (ILC), preoperative MRI scan is considered, the accuracy of diagnosis ...
    • Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN. 

      Fowler, A; Mahamdallie, S; Ruark, E; Seal, S; Ramsay, E; Clarke, M; Uddin, I; Wylie, H; Strydom, A; Lunter, G; Rahman, N (2016-11-25)
      Background: Targeted next generation sequencing (NGS) panels are increasingly being used in clinical genomics to increase capacity, throughput and affordability of gene testing. Identifying whole exon deletions or duplications ...
    • Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration. 

      Croft, DR; Coleman, ML; Li, S; Robertson, D; Sullivan, T; Stewart, CL; Olson, MF (2005-01-17)
      Membrane blebbing during the apoptotic execution phase results from caspase-mediated cleavage and activation of ROCK I. Here, we show that ROCK activity, myosin light chain (MLC) phosphorylation, MLC ATPase activity, and ...
    • Advances and challenges in targeting FGFR signalling in cancer. 

      Babina, IS; Turner, NC (2017-05)
      Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular processes. Deregulation of FGFR signalling is observed in a subset of many cancers, making activated FGFRs a highly promising potential ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06-17)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. 

      Turner, NC; Neven, P; Loibl, S; Andre, F (2017-06-17)
      Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development ...
    • Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. 

      Schmidt, MK; Hogervorst, F; van Hien, R; Cornelissen, S; Broeks, A; Adank, MA; Meijers, H; Waisfisz, Q; Hollestelle, A; Schutte, M; van den Ouweland, A; Hooning, M; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Arndt, V; Bermisheva, M; Bogdanova, NV; Bolla, MK; Brauch, H; Brenner, H; Brüning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dunning, AM; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Haeberle, L; Hall, P; Hillemanns, P; Hopper, JL; Jakubowska, A; John, EM; Jones, M; Khusnutdinova, E; Knight, JA; Kosma, V-M; Kristensen, V; Lee, A; Lindblom, A; Lubinski, J; Mannermaa, A; Margolin, S; Meindl, A; Milne, RL; Muranen, TA; Newcomb, PA; Offit, K; Park-Simon, T-W; Peto, J; Pharoah, PDP; Robson, M; Rudolph, A; Sawyer, EJ; Schmutzler, RK; Seynaeve, C; Soens, J; Southey, MC; Spurdle, AB; Surowy, H; Swerdlow, A; Tollenaar, RAEM; Tomlinson, I; Trentham-Dietz, A; Vachon, C; Wang, Q; Whittemore, AS; Ziogas, A; van der Kolk, L; Nevanlinna, H; Dörk, T; Bojesen, S; Easton, DF (2016-08-10)
      PURPOSE: CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its ...
    • Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. 

      Trabert, B; Poole, EM; White, E; Visvanathan, K; Adami, H-O; Anderson, GL; Brasky, TM; Brinton, LA; Fortner, RT; Gaudet, M; Hartge, P; Hoffman-Bolton, J; Jones, M; Lacey, JV; Larsson, SC; Mackenzie, GG; Schouten, LJ; Sandler, DP; O'Brien, K; Patel, AV; Peters, U; Prizment, A; Robien, K; Setiawan, VW; Swerdlow, A; van den Brandt, PA; Weiderpass, E; Wilkens, LR; Wolk, A; Wentzensen, N; Tworoger, SS; Ovarian Cancer Cohort Consortium (OC3) (2019-02-01)
      BACKGROUND: Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily ...
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses 

      Dowsett, M (2003-11)
      BACKGROUND: The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage ...
    • The anticonvulsive Phenhydan® suppresses extrinsic cell death. 

      Moerke, C; Jaco, I; Dewitz, C; Müller, T; Jacobsen, AV; Gautheron, J; Fritsch, J; Schmitz, J; Bräsen, JH; Günther, C; Murphy, JM; Kunzendorf, U; Meier, P; Krautwald, S (2018-11-15)
      Different forms of regulated cell death-like apoptosis and necroptosis contribute to the pathophysiology of clinical conditions including ischemia-reperfusion injury, myocardial infarction, sepsis, and multiple sclerosis. ...
    • APC/C is an essential regulator of centrosome clustering. 

      Drosopoulos, K; Tang, C; Chao, WC; Linardopoulos, S (2014-01)
      Centrosome amplification has been extensively associated with cancer. Cancer cells with extra centrosomes have the ability to cluster the extra centrosomes and divide in a bipolar fashion. Although a number of proteins ...
    • Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution 

      Stratton, M (2007-09)
      For decades, cytogenetic studies have demonstrated that somatically acquired structural rearrangements of the genome are a common feature of most classes of human cancer. However, the characteristics of these rearrangements ...
    • Assessing HER2 Amplification in Plasma cfDNA. 

      Garcia-Murillas, I; Turner, NC (2018)
      Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...